Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Quantinuum Raises $1.68 Billion in Upsized Nasdaq IPO Amid Growing Quantum Computing Demand 
Honeywell Aerospace Targets $6.5 Billion Earnings by 2030 After Spin-Off 
South Korea Weighs AI Profit Sharing as Samsung and SK Hynix Earnings Surge 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Apollo and Blackstone Complete $35 Billion Anthropic AI Infrastructure Financing Deal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Nvidia Expands South Korea AI Partnerships to Strengthen Data Center and Memory Chip Supply 
Lynas Rare Earths Names Pol Le Roux as Interim CEO Ahead of Leadership Change 
The four types of dementia most people don’t know exist 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
J.P. Morgan Sees Major Upside for Prysmian as Optical Fiber Prices Surge 
MOL Gets More Time to Negotiate Acquisition of Russian-Owned Stake in Serbia’s NIS 
British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug developer Nuvalent Inc. (NASDAQ: NUVL) in a deal that could be worth more than $9 billion, according to a report published by the Financial Times on Tuesday.
Sources familiar with the matter said both companies are working toward finalizing an agreement as early as this week. However, discussions remain ongoing, and there is still a possibility that the deal could fall through if last-minute challenges arise.
If completed, the proposed acquisition would value Massachusetts-headquartered Nuvalent between $9 billion and $10 billion. The valuation represents a substantial premium over Nuvalent’s market capitalization, which stood at nearly $7 billion at the close of trading on Monday.
The potential takeover would mark GSK’s largest acquisition in more than a decade and rank among the most significant transactions in the company’s history. The move aligns with CEO Luke Miels’ strategy to expand and strengthen GSK’s oncology portfolio as the pharmaceutical industry increasingly focuses on innovative cancer treatments.
Nuvalent has gained attention for its work in developing targeted cancer therapies designed to address resistance mechanisms in tumors. Its lead drug candidate, neladalkib, is being developed for the treatment of lung cancer and is currently under review by U.S. regulators. Approval of the therapy could significantly enhance Nuvalent’s value and commercial prospects.
The reported deal comes during a period of heightened activity in the global biotechnology sector. According to Dealogic data cited in the report, biotech and pharmaceutical mergers and acquisitions have reached nearly $211 billion in announced transactions so far this year, highlighting strong demand for promising drug-development companies.
Should the acquisition move forward, it would further reinforce GSK’s commitment to cancer research and provide the company with valuable assets in the rapidly growing oncology market.
